Acquisition of tumor tissue is more challenging in the clinical scenario of acquired resistance following EGFR TKIs treatment, given the spatial and temporal heterogeneity of resistance mechanisms and the need to subject a patient to additional invasive procedure(s) to acquire a timely tissue specimen reflective of the genomic landscape at the time of progression. Here, EGFR is linked to neoplasm.